Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Itmig Sessions – Sunday, November 25

Itmig Sessions – Sunday, November 25 APLCC/ITMIG 2012 Abstracts Volume 7, Number 11, Supplement 5, November 2012 ITMIG SESSIONS – SUNDAY, NOVEMBER 25 ITMIG UPDATES - November 25, 2012 08:30-09:10 ITMIG UPDATES - November 25, 2012 08:30-09:10 TARGETED THERAPIES FOR THYMIC MALIGNANCIES Nicolas Girard Respiratory Medicine, Hospices Civils De Lyon, Bron/FR ANCE Thymic malignancies are rare epithelial tumors that may be aggressive and difficult to treat. Thymomas are usually localized to the anterior mediastinum and are frequently eligible for upfront surgical resection. However, nearly 30% of patients present with locally advanced tumor at time of diagnosis, and chemotherapy is then used to reduce the tumor burden, possibly allowing subsequent surgery and/or radiotherapy. Thymic carcinomas have a tendency towards metastatic spread, and systemic treatment is a major component in the multimodal strategy. Metastatic and recurrent thymic malignancies may similarly be treated with chemotherapy, with limited long-term efficacy, especially beyond first-line treatment. The molecular characterization of thymoma and thymic carcinoma recently led to identify potentially druggable targets; significant preclinical and clinical data are available for the EGF receptor (EGFR), the KIT/mast/stem-cell growth factor receptor, and the IGF-1 receptor (IGF-1R) pathways. While there is currently no rationale to recommend the use of EGFR tyrosine kinase Table of Contents http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Itmig Sessions – Sunday, November 25

Journal of Thoracic Oncology , Volume 7 – Nov 1, 2012
Download PDF
6 pages

Loading next page...
 
/lp/wolters-kluwer-health/itmig-sessions-ndash-sunday-november-25-sIa4bTzrSc

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864

Abstract

APLCC/ITMIG 2012 Abstracts Volume 7, Number 11, Supplement 5, November 2012 ITMIG SESSIONS – SUNDAY, NOVEMBER 25 ITMIG UPDATES - November 25, 2012 08:30-09:10 ITMIG UPDATES - November 25, 2012 08:30-09:10 TARGETED THERAPIES FOR THYMIC MALIGNANCIES Nicolas Girard Respiratory Medicine, Hospices Civils De Lyon, Bron/FR ANCE Thymic malignancies are rare epithelial tumors that may be aggressive and difficult to treat. Thymomas are usually localized to the anterior mediastinum and are frequently eligible for upfront surgical resection. However, nearly 30% of patients present with locally advanced tumor at time of diagnosis, and chemotherapy is then used to reduce the tumor burden, possibly allowing subsequent surgery and/or radiotherapy. Thymic carcinomas have a tendency towards metastatic spread, and systemic treatment is a major component in the multimodal strategy. Metastatic and recurrent thymic malignancies may similarly be treated with chemotherapy, with limited long-term efficacy, especially beyond first-line treatment. The molecular characterization of thymoma and thymic carcinoma recently led to identify potentially druggable targets; significant preclinical and clinical data are available for the EGF receptor (EGFR), the KIT/mast/stem-cell growth factor receptor, and the IGF-1 receptor (IGF-1R) pathways. While there is currently no rationale to recommend the use of EGFR tyrosine kinase Table of Contents

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Nov 1, 2012

There are no references for this article.